Wuhan Hvsen Biotechnology Co Ltd (300871) — Cash Flow-to-Debt Ratio
Wuhan Hvsen Biotechnology Co Ltd (300871) has a Cash Flow-to-Debt Ratio of 0.07x as of September 2025, meaning its operating cash flow of CN¥59.06 Million could theoretically repay 0% of its total liabilities (CN¥839.94 Million) in one year. See Wuhan Hvsen Biotechnology Co Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Wuhan Hvsen Biotechnology Co Ltd Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Wuhan Hvsen Biotechnology Co Ltd across 10 annual periods. Also explore Wuhan Hvsen Biotechnology Co Ltd (300871) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Wuhan Hvsen Biotechnology Co Ltd (2016–2025)
Year-by-year debt coverage analysis for Wuhan Hvsen Biotechnology Co Ltd. For market capitalisation and broader financial context, see market value of Wuhan Hvsen Biotechnology Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.29x | CN¥238.45 Million | CN¥822.17 Million | ▲ +932.3% |
| 2024 | 0.03x | CN¥43.53 Million | CN¥1.55 Billion | ▼ -55.7% |
| 2023 | 0.06x | CN¥92.92 Million | CN¥1.47 Billion | ▼ -5.1% |
| 2022 | 0.07x | CN¥96.68 Million | CN¥1.45 Billion | ▼ -51.8% |
| 2021 | 0.14x | CN¥155.72 Million | CN¥1.12 Billion | ▲ +7.0% |
| 2020 | 0.13x | CN¥48.35 Million | CN¥373.08 Million | ▼ -66.5% |
| 2019 | 0.39x | CN¥105.24 Million | CN¥271.80 Million | ▲ +160.8% |
| 2018 | 0.15x | CN¥21.10 Million | CN¥142.08 Million | ▼ -77.7% |
| 2017 | 0.67x | CN¥80.56 Million | CN¥121.06 Million | ▲ +12.2% |
| 2016 | 0.59x | CN¥60.00 Million | CN¥101.16 Million | — |